VBP15, a Novel Anti-Inflammatory, is Effective at Reducing the Severity of Murine Experimental Autoimmune Encephalomyelitis
Blythe C. Dillingham(Children's National), Jesse M. Damsker(ReveraGen BioPharma (United States)), Erica Reeves(ReveraGen BioPharma (United States)), Amanda M. Mullen(Children's National), Susan M. Knoblach(Children's National), Luca Bello(Children's National), Gina M. Many(Pacific Northwest National Laboratory), Eric P. Hoffman(Children's National), Brennan Harmon(Children's National), Edward M. Connor(ReveraGen BioPharma (United States)), Christopher R. Heier(Children's National), John M. McCall(ReveraGen BioPharma (United States)), Kanneboyina Nagaraju(George Washington University)
Cited by 26
Related Papers
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k
Expression Profiling in the Muscular Dystrophies
|The Journal of Cell Biology|2000|481
Ribosome biogenesis may augment resistance training-induced myofiber hypertrophy and is required for myotube growth in vitro
|American Journal of Physiology-Endocrinology and Metabolism|2016|164